Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Dupilumab: Eerste resultaten vanuit het BioDay-register
Translated title of the contribution
:
Dupilumab: Initial results from the BioDay registry
Lieneke F.M. Ariëns
, J. van der Schaft
, D. S. Bakker
, D. M.W. Balak
, B. Giovannone
, M. Romeijn
, T. Kouwenhoven
, M. Kamsteeg
, J. Drylewicz
, F. van Wijk
,
S. Nierkens
, J. L. Thijs
, M. L. Schuttelaar
, M. S. de Bruin-Weller
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dupilumab: Initial results from the BioDay registry'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Dupilumab
100%
Everyday Practices
50%
Atopic Dermatitis
50%
Clinically Significant
37%
Clinical Efficacy
37%
Moderate-to-severe Atopic Dermatitis
25%
Difficult-to-treat
25%
Pruritus
25%
Number of Patients
12%
Adult Patients
12%
Quality of Life
12%
Patient-Reported Outcomes Measurement Information System (PROMIS)
12%
Treatment Failure
12%
Patient-reported Outcomes
12%
Phase III Clinical Trial
12%
Clinical Safety
12%
Immunosuppressive Drugs
12%
Multicenter Registry
12%
Practice Data
12%
Practice Setting
12%
Conjunctivitis
12%
Percent Change
12%
EASI Score
12%
Itch
12%
Eosinophilia
12%
Nursing and Health Professions
Dupilumab
100%
Atopic Dermatitis
75%
Pruritus
37%
Clinical Effectiveness
37%
Patient-Reported Outcome
25%
Dermatology Life Quality Index
25%
Quality of Life
12%
Side Effect
12%
Physical Disease by Body Function
12%
Practice Setting
12%
Immunosuppressive Agent
12%
Conjunctivitis
12%
Eosinophilia
12%
Pharmacology, Toxicology and Pharmaceutical Science
Dupilumab
100%
Atopic Dermatitis
75%
Pruritus
37%
Clinical Trial
12%
Side Effect
12%
Immunosuppressive Agent
12%
Physical Disease by Body Function
12%
Eosinophilia
12%